Why the experience of key pharmaceutical companies

ncycgdxhl · Wysłany: Wto 23:50, 15 Mar 2011

Why the experience of key pharmaceutical companies

7 A ADCA business, both sides are willing to adopt a joint venture company of Xinhua profit of 33.2 million yuan last year in the first half, but gradually this year as domestic production scale, the impact of low prices of imported 7 a ADCA prices, resulting in a loss company is now willing to adopt 7.28 million yuan. 7 Although the ACA is still a stone pharmaceutical drugs and Hebei in the world run. But potential rivals have already began to stir, 7, ACA is now a shift from a seller's supply and demand balance, the future of this situation can be maintained without b. If the price volatility from the market regulator, then the reduction in export tax rebates is the transition to a market economy country embodiment. From January 1 this year began, the pharmaceutical industry cut the export tax rebate rate of 2 to 4 percentage points. Policy factors are also a lot less interest in recent years, pharmaceutical companies can be said to regulate and adjust the years. Certification, environmental and packaging costs in the enterprise policy into a certain proportion. Yu Guanwen said in the past many companies, although when the project is launched the At that time the policy is to pay a fine of corporate emissions violations, fines can enter the cost, in this case, many enterprises are too many outstanding loans in environmental protection. Norms of environmental protection is gradually now, companies do not spend a small number of environmental costs. He said 10,000 tons of penicillin industrial salt wastewater treatment plant equipment needs 30 million yuan, and a year running costs are up to 150 million. GMP certification in the production process to bring the whole industry, product quality, raise the level of equipment at the same time,[link widoczny dla zalogowanych], companies are paying a high price, resulted in substantial expansion opportunity through the certification of equipment idle, so that enterprises will be tasted in the next time consequences. but more crowded. Minister of Planning and Development Hayao Wangya Bin said that the state required by the end of this year natural cork bottle stoppers antibiotics into butyl rubber stopper, a butyl rubber stopper expensive than natural rubber plug 4 cents, Hayao 3.0 billion a year needed Only a year increase in cost is more than 1200 million. Now the market is very competitive, a price increase of 4 cents penicillin market will not accept only the enterprises themselves increase the cost of digestion. System is the soft underbelly of 2004, pharmaceutical companies can be said to be bruised and battered, the policy of extrusion, the adverse market environment, the problems faced by the enterprise at the same time. But the focus of pharmaceutical companies face the cold wind was blowing the first underlying causes of its own. Beijing Golden Sun Jianbin drug network industry analyst, said the two hundred from the first quarter ranking, the most viable non-performing assets are stripped off after the joint-stock enterprises, and state-owned enterprises the most problems. The most prominent is the product structure, raw material medicine and antibiotics are almost all concentrated in the key state-owned enterprises, antibiotic price, pharmacy prescription sales; bulk drugs market price fluctuations have led to state-owned key enterprise business benefits fell more quickly than others. Sun Jianbin that state-owned enterprises in the environment can not change the premise, the key is to introduce modern corporate management mechanism, internal governance and external monitoring. In the expansion scale enterprises can not blindly,[link widoczny dla zalogowanych], to prevent acquisition of indigestion. Yu Guanwen that the pharmaceutical industry in the eyes of many people is a high-tech, high growth, high input, high output, high-risk sunrise industry, and people just fancy more of its high growth and high-yield side,[link widoczny dla zalogowanych], in fact, should see the high-risk and high investment on the other hand. Corporate investors and managers should be to prevent the blind expansion,[link widoczny dla zalogowanych], investment in research efforts and improve the technical level. He disclosed that last year China's pharmaceutical industry investment in R & D is only about 1% of sales. Foreign pharmaceutical companies are generally listed on a variety of 2 to 3 years after follow-up of the product should have follow-up, and our present very few truly new drugs, the competitiveness of enterprises out of the question. Sun Jianbin expected slowdown in the second half of the pharmaceutical industry will continue to increase profits, some companies will increase efficiency decline, The Harbin Pharmaceutical, Xinhua reply came on the company's future: We can only bite persisted. Together the prices of companies like antibiotics increase the cost of excess capacity, vicious market competition,[link widoczny dla zalogowanych], domestic 15 large antibiotics to save their own helplessness, 7 production and sales survey at the end of consensus: From August 1, these companies together raise part of penicillin, · r5 ·